华银健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模7577.66万。今年以来收益 20.43%，同类排名364/8891；近一年收益23.33%，同类排名4141/8137；成立以来收益38.5%。 华银健康生活主题灵活配置（001056）基金经理为庞文杰。 2月27日，天智航涨5.11%，截至发稿，报25.92元/股，成交2.24亿元，换手率1.98%，总市值118.19亿 元。 资料显示，北京天智航医疗科技股份有限公司位于北京市海淀区建枫路(南延)中关村西三旗金隅科技园 8号院2号楼，成立日期2010年10月22日，上市日期2020年7月7日，公司主营业务涉及专注于骨科手术导 航定位机器人的研发、生产、销售和服务。主营业务收入构成为：骨科手术导航定位机器人58.31%， 配套设备及耗材23.86%，技术服务16.49%，其他(补充)1.31%，其他0.04%。 从基金十大重仓股角度 数据显示，华银基金管理旗下1只基金重仓天智航。华银健康生活主题灵活配置（001056）四季度减持3 万股，持有股数20万股，占基金净值比例为4.01%，位居第十大重仓股。根据测算，今日浮盈赚取约 2 ...

Group 1 - Tianzhihang Medical Technology Co., Ltd. experienced a stock price increase of 5.43%, reaching 26.19 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 1.42%, resulting in a total market capitalization of 11.942 billion CNY [1] - The company, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [1] - The revenue composition of the company includes: orthopedic surgical navigation robots (58.31%), supporting equipment and consumables (23.86%), technical services (16.49%), and other (1.31%) [1] Group 2 - Galaxy Fund holds a significant position in Tianzhihang, with the Galaxy Kangle Stock A fund (519673) owning 467,900 shares, representing 5% of the fund's net value, making it the ninth-largest holding [2] - The Galaxy Kangle Stock A fund has a current size of 141 million CNY and has achieved a year-to-date return of 18.34%, ranking 89 out of 5,569 in its category [2] - The fund manager, Fang Wei, has been in charge for 4 years and 280 days, with the fund's total assets amounting to 576 million CNY, and the best and worst returns during his tenure being 2.42% and -12.24%, respectively [2]

Group 1 - Tianzhihang's stock price fell by 2.36% to 24.84 yuan per share, with a total market capitalization of 11.327 billion yuan, and a cumulative decline of 8.17% over three consecutive days [1] - The company, Beijing Tianzhihang Medical Technology Co., Ltd., focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with main business revenue composition: 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] Group 2 - E Fund's ETF, E Fund National Robot Industry ETF (159530), entered Tianzhihang's top ten circulating shareholders, holding 10.7803 million shares, accounting for 2.38% of circulating shares, with a floating loss of approximately 6.4682 million yuan today [2] - The E Fund National Robot Industry ETF has a total scale of 15.267 billion yuan, with a year-to-date return of 0.81% and a one-year return of 20.43% [2] - Fund managers Li Shujian and Li Xu have managed the fund for 2 years and 3 years respectively, with the best returns during their tenure being 118.55% and 166.96% [2]

Group 1 - Tianzhihang Medical Technology Co., Ltd. experienced a stock price increase of 5.17%, reaching 25.23 CNY per share, with a trading volume of 305 million CNY and a turnover rate of 2.72%, resulting in a total market capitalization of 11.505 billion CNY [1] - The company, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots. The revenue composition is as follows: orthopedic surgical navigation robots 58.31%, supporting equipment and consumables 23.86%, technical services 16.49%, and others 1.31% [1] Group 2 - Among the top ten circulating shareholders of Tianzhihang, Huaxia Fund's Huaxia CSI Robot ETF (562500) increased its holdings by 1.6284 million shares in the third quarter, holding a total of 8.7238 million shares, which accounts for 1.93% of the circulating shares. The estimated floating profit today is approximately 10.8175 million CNY [2] - The Huaxia CSI Robot ETF (562500) was established on December 17, 2021, with a latest scale of 26.465 billion CNY. Year-to-date returns are 4.34%, ranking 2777 out of 5566 in its category; the one-year return is 30.24%, ranking 2430 out of 4285; and since inception, the return is 6.23% [2] Group 3 - The fund manager of Huaxia CSI Robot ETF (562500) is Hualong. As of the report date, Hualong has served for 3 years and 169 days, with total fund assets of 39.451 billion CNY. The best fund return during the tenure is 209.94%, while the worst return is -15.08% [3]

Group 1 - Tianzhihang experienced a 5% decline on January 20, with a stock price of 21.26 yuan per share, a trading volume of 341 million yuan, a turnover rate of 3.44%, and a total market capitalization of 9.694 billion yuan [1] - Beijing Tianzhihang Medical Technology Co., Ltd. focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with main business revenue composition: 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] Group 2 - E Fund's ETF, E Fund Guozheng Robot Industry ETF (159530), entered the top ten circulating shareholders of Tianzhihang in the third quarter, holding 10.7803 million shares, accounting for 2.38% of circulating shares, with an estimated floating loss of approximately 12.074 million yuan [2] - E Fund Guozheng Robot Industry ETF (159530) was established on January 10, 2024, with a latest scale of 13.315 billion yuan, and has achieved a year-to-date return of 6.39%, ranking 2365 out of 5542 in its category, and a one-year return of 41.12%, ranking 1878 out of 4235 [2] Group 3 - The fund managers of E Fund Guozheng Robot Industry ETF (159530) are Li Shujian and Li Xu, with total fund assets of 19.758 billion yuan and 26.538 billion yuan respectively, achieving best returns of 136.18% and 175.17% during their tenure [3]

Core Viewpoint - Tianzhihang's stock price has shown significant volatility, with a year-to-date increase of 44.37%, but a recent decline of 2.01% on January 20, 2025, indicating potential market fluctuations and investor sentiment shifts [1]. Group 1: Company Overview - Tianzhihang Medical Technology Co., Ltd. is located in Haidian District, Beijing, and was established on October 22, 2010, with its IPO on July 7, 2020 [1]. - The company's main business focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with revenue composition as follows: 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1]. Group 2: Financial Performance - For the period from January to September 2025, Tianzhihang achieved operating revenue of 187 million yuan, representing a year-on-year growth of 103.51%, while the net profit attributable to shareholders was -114 million yuan, a decrease of 49.73% year-on-year [2]. - As of September 30, 2025, the number of shareholders increased by 12.31% to 17,300, with an average of 26,094 circulating shares per person, a decrease of 10.96% [2]. Group 3: Market Activity - On January 20, 2025, Tianzhihang's stock experienced a trading volume of 78.62 million yuan, with a turnover rate of 0.77% and a total market capitalization of 10 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on January 14, 2025 [1]. - Institutional holdings as of September 30, 2025, show that E Fund's National Robot Industry ETF is the sixth largest circulating shareholder with 10.78 million shares, while Huaxia's CSI Robot ETF is the eighth largest with 8.72 million shares, an increase of 1.63 million shares from the previous period [2].

Group 1 - Tianzhihang Medical Technology Co., Ltd. focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] - As of January 12, Tianzhihang's stock price increased by 5.46% to 18.94 CNY per share, with a total market capitalization of 8.636 billion CNY and a trading volume of 9.9702 million CNY [1] Group 2 - Huaxia Fund's Huaxia CSI Robot ETF (562500) increased its holdings in Tianzhihang by 1.6284 million shares in the third quarter, bringing its total holdings to 8.7238 million shares, which represents 1.93% of the circulating shares [2] - The Huaxia CSI Robot ETF has a total asset size of 22.798 billion CNY and has achieved a year-to-date return of 4.35%, ranking 2512 out of 5579 in its category [2] Group 3 - The fund manager of Huaxia CSI Robot ETF is Hualong, who has been in the position for 3 years and 145 days, with the fund's total asset size at 35.957 billion CNY and a best return of 139.26% during the tenure [3]

Group 1 - Tianzhihang Medical Technology Co., Ltd. focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] - As of January 5, Tianzhihang's stock price increased by 5% to 15.95 CNY per share, with a trading volume of 60.94 million CNY and a turnover rate of 0.85%, resulting in a total market capitalization of 7.273 billion CNY [1] Group 2 - E Fund's ETF, E Fund Guozheng Robotics Industry ETF (159530), entered Tianzhihang's top ten circulating shareholders in the third quarter, holding 10.78 million shares, which is 2.38% of the circulating shares, with an estimated floating profit of approximately 8.1931 million CNY [2] - The E Fund Guozheng Robotics Industry ETF has a current scale of 13.315 billion CNY and has achieved a year-to-date return of 36.58%, ranking 1266 out of 4189 in its category [2] Group 3 - The fund managers of E Fund Guozheng Robotics Industry ETF are Li Shujian and Li Xu, with total fund assets of 19.758 billion CNY and 26.538 billion CNY respectively [3] - Li Shujian has a tenure of 2 years and 120 days, with the best fund return of 114.87% and the worst return of -6.47% during his tenure [3] - Li Xu has a tenure of 3 years and 42 days, with the best fund return of 139.24% and the worst return of -5.57% during his tenure [3]

Core Viewpoint - Tianzhihang's stock price has experienced a decline recently, despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1]. - The company was established on October 22, 2010, and went public on July 7, 2020 [1]. Financial Performance - For the period from January to September 2025, Tianzhihang reported a revenue of 187 million yuan, representing a year-on-year growth of 103.51%. However, the net profit attributable to shareholders was -114 million yuan, a decrease of 49.73% compared to the previous year [2]. - The stock price has increased by 55.26% year-to-date, but has seen declines of 8.76% over the last five trading days, 12.22% over the last twenty days, and 22.18% over the last sixty days [1]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.31% to 17,300, with an average of 26,094 shares held per shareholder, a decrease of 10.96% [2]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million yuan [1]. Market Position - Tianzhihang is categorized under the pharmaceutical and biological industry, specifically in medical devices, and is associated with concepts such as robotics, specialized innovation, and medical equipment [2].

Core Viewpoint - Tianzhihang's stock price has shown significant volatility, with a year-to-date increase of 73.77%, but recent declines in the short term indicate potential market fluctuations [2]. Group 1: Stock Performance - As of October 31, Tianzhihang's stock price rose by 2.06% to 17.36 CNY per share, with a trading volume of 25.985 million CNY and a turnover rate of 0.33%, resulting in a total market capitalization of 7.916 billion CNY [1]. - Year-to-date, Tianzhihang's stock has increased by 73.77%, but it has experienced a decline of 1.92% over the last five trading days, 1.31% over the last 20 days, and 2.03% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Tianzhihang reported revenue of 187 million CNY, representing a year-on-year growth of 103.51%. However, the net profit attributable to shareholders was -114 million CNY, a decrease of 49.73% year-on-year [3]. - The company's main business revenue composition includes 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [2]. Group 3: Shareholder Information - As of September 30, 2025, Tianzhihang had 17,300 shareholders, an increase of 12.31% from the previous period, with an average of 26,094 circulating shares per shareholder, a decrease of 10.96% [3]. - Among the top ten circulating shareholders, the E Fund National Robot Industry ETF holds 10.7803 million shares, marking its entry as a new shareholder, while the Huaxia CSI Robot ETF increased its holdings by 1.6284 million shares to 8.7238 million shares [3].